NASDAQ:VXRT - Vaxart Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.31 +0.11 (+2.12 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$5.20
Today's Range$5.16 - $6.25
52-Week Range$4.73 - $11.88
Volume820,540 shs
Average Volume71,495 shs
Market Capitalization$37.85 million
P/E Ratio-0.67
Dividend YieldN/A
Beta0.06

About Vaxart (NASDAQ:VXRT)

Vaxart logoVaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VXRT
CUSIPN/A
Phone650-550-3500

Debt

Debt-to-Equity Ratio0.10
Current Ratio4.09
Quick Ratio4.09

Price-To-Earnings

Trailing P/E Ratio-0.67
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.90 million
Price / Sales4.26
Cash FlowN/A
Price / CashN/A
Book Value$5.32 per share
Price / Book1.00

Profitability

EPS (Most Recent Fiscal Year)($8.36)
Net Income$-29,400,000.00
Net Margins-286.74%
Return on Equity-202.17%
Return on Assets-37.17%

Miscellaneous

Employees16
Outstanding Shares7,140,000

Vaxart (NASDAQ:VXRT) Frequently Asked Questions

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart shares reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

How were Vaxart's earnings last quarter?

Vaxart (NASDAQ:VXRT) issued its earnings results on Tuesday, May, 15th. The biotechnology company reported $0.49 earnings per share for the quarter. The biotechnology company earned $1.50 million during the quarter. Vaxart had a negative net margin of 286.74% and a negative return on equity of 202.17%. View Vaxart's Earnings History.

Who are some of Vaxart's key competitors?

Who are Vaxart's key executives?

Vaxart's management team includes the folowing people:
  • Wouter Latour M.D., President, Chief Executive Officer, Director
  • , Bio & Compensation - 
  • John M. Harland, Chief Financial Officer
  • Sean N. Tucker Ph.D., Chief Scientific Officer
  • , Bio & Compensation - 
  • Michael J. Finney Ph.D., Director
  • , Bio & Compensation - 
  • Jan Leschly, Director
  • Richard J. Markham, Director
  • Geoffrey F. Cox Ph.D., Independent Director
  • John P. Richard, Independent Director

Has Vaxart been receiving favorable news coverage?

Press coverage about VXRT stock has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vaxart earned a coverage optimism score of 0.19 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.99 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Vaxart's major shareholders?

Vaxart's stock is owned by many different of retail and institutional investors. Top institutional investors include CARE CAPITAL III LLC (39.40%), BlackRock Inc. (0.57%) and GABELLI & Co INVESTMENT ADVISERS INC. (0.26%). View Institutional Ownership Trends for Vaxart.

Which major investors are buying Vaxart stock?

VXRT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc. and GABELLI & Co INVESTMENT ADVISERS INC.. View Insider Buying and Selling for Vaxart.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $5.31.

How big of a company is Vaxart?

Vaxart has a market capitalization of $37.85 million and generates $8.90 million in revenue each year. The biotechnology company earns $-29,400,000.00 in net income (profit) each year or ($8.36) on an earnings per share basis. Vaxart employs 16 workers across the globe.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]


MarketBeat Community Rating for Vaxart (VXRT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  186
MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote "Outperform" if you believe VXRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vaxart (NASDAQ:VXRT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Vaxart in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$5.00
Price Target Upside: N/AN/AN/A762.07% upside

Vaxart (NASDAQ:VXRT) Consensus Price Target History

Price Target History for Vaxart (NASDAQ:VXRT)

Vaxart (NASDAQ:VXRT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2017HC WainwrightReiterated RatingHoldN/AView Rating Details
2/14/2017Ladenburg ThalmannDowngradeBuy ➝ NeutralN/AView Rating Details
11/7/2016FBR & CoReiterated RatingBuyN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Vaxart (NASDAQ:VXRT) Earnings History and Estimates Chart

Earnings by Quarter for Vaxart (NASDAQ:VXRT)

Vaxart (NASDAQ VXRT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018Q3 2018$0.49$1.50 millionViewN/AView Earnings Details
2/6/2018Q2 2018($0.09)$2.70 millionViewN/AView Earnings Details
11/2/2017Q1 2018($0.14)($0.14)$0.30 million$0.10 millionViewN/AView Earnings Details
8/31/2017Q4 2017($0.17)($0.15)$0.50 million$0.10 millionViewN/AView Earnings Details
5/4/2017Q3 2017($0.2150)($0.11)$2.90 million$4.90 millionViewN/AView Earnings Details
2/2/2017Q2 2017($0.18)($0.23)$1.95 million$3.80 millionViewListenView Earnings Details
11/3/2016Q117($0.28)($0.26)$1.80 million$0.10 millionViewListenView Earnings Details
9/14/2016Q4$0.25($0.18)$15.47 million$0.60 millionViewListenView Earnings Details
5/5/2016Q3($0.18)($0.14)$1.70 million$5.30 millionViewListenView Earnings Details
2/5/2016Q2($0.11)($0.17)$13.90 million$1.70 millionViewN/AView Earnings Details
11/6/2015Q116($0.17)$1.70 millionViewN/AView Earnings Details
9/11/2015Q315($0.55)$4.10 millionViewListenView Earnings Details
5/7/2015Q3 2015$0.03$5.90 millionViewN/AView Earnings Details
2/5/2015Q215($0.09)$0.19$7.40 million$13.90 millionViewN/AView Earnings Details
11/7/2014Q115($0.12)($0.20)$5.60 million$0.70 millionViewN/AView Earnings Details
9/26/2014Q414($0.29)$8.50 millionViewN/AView Earnings Details
5/6/2014Q3 2014($0.28)$0.09$29.50 millionViewN/AView Earnings Details
11/7/2013Q313($0.14)$12.30 millionViewN/AView Earnings Details
9/18/2013Q4 13($0.23)$9.30 millionViewN/AView Earnings Details
5/10/2013Q3 2013$0.01$12.50 millionViewN/AView Earnings Details
2/12/2013Q2 2013($0.11)ViewN/AView Earnings Details
11/8/2012Q312($0.12)$1.10 millionViewN/AView Earnings Details
8/9/2012Q4 2012($0.38)ViewN/AView Earnings Details
5/10/2012Q3 2012($0.20)ViewN/AView Earnings Details
3/14/2012Q2 2012($0.28)ViewN/AView Earnings Details
11/2/2011($0.09)($0.07)ViewN/AView Earnings Details
8/3/2011($0.23)($0.11)ViewN/AView Earnings Details
5/5/2011($0.18)$0.05ViewN/AView Earnings Details
3/8/2011($0.08)($0.15)ViewN/AView Earnings Details
11/3/2010Q1 2011$0.30$0.73ViewN/AView Earnings Details
8/5/2010Q4 2010($0.48)($0.46)ViewN/AView Earnings Details
5/6/2010Q3 2010($0.42)$0.67ViewN/AView Earnings Details
3/10/2010Q2 2010($0.66)$0.13ViewN/AView Earnings Details
11/5/2009Q1 2010($0.84)ViewN/AView Earnings Details
8/6/2009Q4 2009($0.68)ViewN/AView Earnings Details
5/6/2009Q3 2009($0.42)($0.83)ViewN/AView Earnings Details
3/11/2009Q2 2009($0.42)($0.32)ViewN/AView Earnings Details
11/6/2008Q1 2009($0.50)ViewN/AView Earnings Details
8/6/2008Q4 2008($0.43)ViewN/AView Earnings Details
5/8/2008Q3 2008($0.76)ViewN/AView Earnings Details
2/28/2008Q2 2008($0.72)($0.42)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vaxart (NASDAQ:VXRT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vaxart (NASDAQ VXRT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.80%
Institutional Ownership Percentage: 9.09%
Insider Trading History for Vaxart (NASDAQ:VXRT)

Vaxart (NASDAQ VXRT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2016Mark P. ColonneseCFOBuy7,000$1.41$9,870.007,000View SEC Filing  
9/25/2015Joseph M. PattiCEOBuy5,000$1.87$9,350.00126,128View SEC Filing  
6/22/2015Anne VanlentDirectorBuy35,000$2.20$77,000.00View SEC Filing  
6/9/2015James FoxDirectorBuy70,000$1.99$139,300.00View SEC Filing  
3/27/2015Joseph M PattiCEOBuy20,000$2.28$45,600.00View SEC Filing  
6/30/2014Joseph M PattiEVPBuy10,000$2.86$28,600.00View SEC Filing  
6/27/2014Joseph M PattiEVPBuy5,000$2.81$14,050.00View SEC Filing  
6/11/2014Joseph M PattiEVPBuy14,467$2.62$37,903.54View SEC Filing  
6/11/2014Russell H PlumbCEOBuy32,031$2.99$95,772.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vaxart (NASDAQ VXRT) News Headlines

Source:
DateHeadline
Vaxart (VXRT) Issues Quarterly  Earnings ResultsVaxart (VXRT) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 16 at 10:52 AM
Vaxart Announces First Quarter 2018 Financial Results and Corporate UpdateVaxart Announces First Quarter 2018 Financial Results and Corporate Update
finance.yahoo.com - May 16 at 8:22 AM
Vaxart Announces $5 Million Inavir® Revenue MilestoneVaxart Announces $5 Million Inavir® Revenue Milestone
finance.yahoo.com - April 20 at 3:21 PM
Vaxart Appoints Brant Biehn as Senior Vice President, Commercial OperationsVaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations
finance.yahoo.com - April 19 at 3:22 PM
Vaxart to Present at Two Upcoming Medical MeetingsVaxart to Present at Two Upcoming Medical Meetings
finance.yahoo.com - April 17 at 7:25 AM
Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine CongressVaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress
finance.yahoo.com - April 3 at 6:54 AM
Vaxart (VXRT) Receives Hold Rating from HC WainwrightVaxart (VXRT) Receives Hold Rating from HC Wainwright
www.americanbankingnews.com - April 2 at 6:59 PM
Vaxart (VXRT) Stock Rating Upgraded by ValuEngineVaxart (VXRT) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 8:45 PM
Who Really Owns Vaxart Inc (NASDAQ:VXRT)?Who Really Owns Vaxart Inc (NASDAQ:VXRT)?
finance.yahoo.com - March 22 at 3:18 PM
Analyzing Vaxart (VXRT) and Its RivalsAnalyzing Vaxart (VXRT) and Its Rivals
www.americanbankingnews.com - March 16 at 11:14 AM
Zacks: Vaxart Inc (VXRT) Given Consensus Rating of "Hold" by BrokeragesZacks: Vaxart Inc (VXRT) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 13 at 9:26 PM
Vaxart (VXRT) vs. The Competition Head-To-Head AnalysisVaxart (VXRT) vs. The Competition Head-To-Head Analysis
www.americanbankingnews.com - March 10 at 7:16 PM
Vaxart Expands Intellectual Property Portfolio With U.S. Patent AllowanceVaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance
finance.yahoo.com - March 7 at 3:18 PM
Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious DiseasesVaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases
finance.yahoo.com - March 2 at 3:18 PM
Vaxart (VXRT) & Its Competitors Financial ContrastVaxart (VXRT) & Its Competitors Financial Contrast
www.americanbankingnews.com - February 27 at 5:14 AM
Analyzing Proteostasis Therapeutics (PTI) & Vaxart (VXRT)Analyzing Proteostasis Therapeutics (PTI) & Vaxart (VXRT)
www.americanbankingnews.com - February 22 at 12:42 PM
Zacks: Vaxart Inc (VXRT) Given Average Recommendation of "Hold" by AnalystsZacks: Vaxart Inc (VXRT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 18 at 1:12 AM

SEC Filings

Vaxart (NASDAQ:VXRT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vaxart (NASDAQ:VXRT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vaxart (NASDAQ VXRT) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.